Novartis strikes $7.8 billion mRNA deal with China's Abogen after a bruising year
The Swiss drugmaker will pay $575 million upfront for global rights to an experimental autoimmune therapy that uses mRNA to destroy disease-causing cells. The deal comes months after two late-stage trial failures wiped around $30 billion from Novartis's market value.
2 min read